CapsoVision, Inc. (CV) AI Stock Analysis

• Market Cap: $327.90M
• Dividend Yield: N/A
• Average Volume (3M): 45.47K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.48
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 90
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): -0.17
• Shares Outstanding: 46,843,224
• 10 Day Avg. Volume: 21,973
• 30 Day Avg. Volume: 45,470
• PEG Ratio: 0.00
• Price to Book (P/B): -1.04
• Price to Sales (P/S): 11.50
• P/FCF Ratio: -6.68
• Enterprise Value/Market Cap: 0.63
• Enterprise Value/Revenue: 21.47
• Enterprise Value/Gross Profit: 39.64
• Enterprise Value/Ebitda: -11.80
• 1Y Price Target: $10.50
• Price Target Upside: -20.63% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $7.00 ▼(-47.09% Downside)

The score is primarily held down by very weak financial performance (losses, negative operating/free cash flow, and negative equity) and bearish technicals (price below key moving averages with weak momentum). Positive FDA-related corporate developments provide some upside potential but do not offset the current financial and trend risks.

Positive Factors

510(k) AI-assisted module submission

Regulatory clearance would enable U.S. commercialization of an AI module integrated with CapsoCam, providing durable clinical workflow and diagnostic differentiation. Approval could expand recurring disposables and cloud services revenue and strengthen long-term competitive positioning.

Breakthrough Device Designation request

A Breakthrough designation for early pancreatic cancer detection could accelerate development and clinical validation. If granted, expedited review and visibility would help establish first-mover status in a high-need indication, materially widening sustainable market opportunity.

Experienced finance leadership added

Adding a seasoned finance executive with capital markets and accounting experience strengthens financial oversight and fundraising capability. Better capital allocation, reporting discipline, and investor engagement support execution of commercialization and R&D plans over the medium term.

Negative Factors

Negative stockholders' equity

Negative equity is a structural solvency concern that limits financing options and increases counterparty and covenant risk. This weakness can restrict growth investments, hamper supplier or partner negotiations, and force dilutive or expensive capital raises to sustain operations.

Negative operating and free cash flow

Persistently negative operating and free cash flows indicate the business is not self-funding its growth. Continued cash burn raises reliance on external financing, constrains R&D and commercialization investments, and increases dilution or insolvency risk absent a clear path to positive cash generation.

Negative profitability and declining margins

Growing revenue paired with worsening margins signals structural cost or pricing issues and challenges scaling profitably. Without margin recovery, long-term profitability and free cash flow generation will remain uncertain, limiting ability to reinvest and deliver sustainable shareholder returns.

CapsoVision, Inc. Business Overview & Revenue Model

Company Description

CapsoVision, Inc. (CV) is a pioneering company in the medical technology sector, specializing in the development of innovative gastrointestinal imaging solutions. The company focuses on enhancing patient care through its flagship product, the CapsoCam, a capsule endoscopy system designed to provide high-quality images of the gastrointestinal tract with minimal discomfort for patients. CapsoVision aims to improve diagnostic capabilities and patient outcomes by leveraging advanced imaging technologies and a commitment to continuous innovation in the field of gastrointestinal health.

How the Company Makes Money

CapsoVision generates revenue primarily through the sale of its CapsoCam capsule endoscopy systems and related disposable products, such as the capsules used in procedures. The company also earns revenue from partnerships with healthcare providers and institutions, which may include training, support services, and bulk purchase agreements. Additionally, CapsoVision may explore collaborations with pharmaceutical companies for research and clinical trials, further diversifying its revenue streams. The company's business model is built on establishing a strong presence in hospitals and outpatient clinics, aiming to create long-term relationships that lead to repeat purchases and ongoing service contracts.

CapsoVision, Inc. Financial Statement Overview

Summary

CapsoVision, Inc. is facing significant financial challenges, with negative profitability, weak balance sheet metrics, and poor cash flow performance. The company needs to address its operational inefficiencies and improve its financial structure to ensure long-term viability.

Income Statement

CapsoVision, Inc. shows a concerning financial performance with negative net profit margins and declining EBIT and EBITDA margins. The company experienced a revenue growth of 20.5% from the previous year, but this was overshadowed by significant losses, indicating inefficiencies in cost management and operations.

Balance Sheet

The balance sheet reflects a negative stockholders' equity, which is a critical concern, indicating that liabilities exceed assets. The debt-to-equity ratio is negative due to the negative equity, and the return on equity is also negative, highlighting poor financial health and potential solvency issues.

Cash Flow

The cash flow statement reveals negative operating and free cash flows, suggesting liquidity challenges. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is closely aligned with net income, but both are negative, which is a red flag for financial sustainability.

Breakdown	TTM	Dec 2024	Dec 2023
Income Statement
Total Revenue	9.64M	11.76M	9.75M
Gross Profit	5.22M	6.38M	5.49M
EBITDA	-17.53M	-19.40M	-10.96M
Net Income	-17.92M	-19.90M	-11.30M
Balance Sheet
Total Assets	25.66M	16.80M	21.53M
Cash, Cash Equivalents and Short-Term Investments	17.79M	9.32M	14.56M
Total Debt	978.00K	1.24M	1.51M
Total Liabilities	5.22M	146.31M	131.37M
Stockholders Equity	20.44M	-129.51M	-109.84M
Cash Flow
Free Cash Flow	-15.26M	-20.24M	-11.56M
Operating Cash Flow	-15.18M	-20.09M	-10.80M
Investing Cash Flow	-82.00K	-153.00K	-754.00K
Financing Cash Flow	23.59M	15.07M	20.53M

CapsoVision, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
A	73 Outperform	$41.32B	32.49	20.62%	0.72%	6.73%	3.34%
NVST	69 Neutral	$3.88B	282.54	0.50%	―	4.73%	―
ANGO	56 Neutral	$414.23M	-14.93	-15.26%	―	2.73%	87.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CV	43 Neutral	$327.90M	―	―	―	―	―

CapsoVision, Inc. Corporate Events

CapsoVision Seeks FDA Clearance for AI Endoscopy Module

On December 29, 2025, CapsoVision, Inc. announced it had submitted a 510(k) application to the U.S. Food and Drug Administration for an AI-assisted reading module for its CapsoCam Plus capsule endoscopy system, a move aimed at improving detection of clinically significant small bowel pathology and reducing clinician review time. The company positions the AI module, supported by an in-house AI capability, a large and growing imaging dataset, and a fully cloud-based architecture, as a differentiator versus competing capsule endoscopy systems, potentially enhancing workflow efficiency, diagnostic accuracy, and accessibility for gastrointestinal practices once regulatory clearance enables U.S. commercialization.

The most recent analyst rating on (CV) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.

CapsoVision Seeks FDA Breakthrough Status for CapsoCam

On November 10, 2025, CapsoVision announced the submission of an application to the FDA for Breakthrough Device Designation for its CapsoCam UGI capsule endoscopy system, aimed at early-stage pancreatic cancer detection. This non-invasive technology could significantly impact the early diagnosis of pancreatic ductal adenocarcinoma, one of the deadliest cancers, by providing a patient-friendly alternative to current invasive diagnostic methods. If granted, the designation would expedite the development process and potentially improve survival rates by enabling earlier detection and treatment.

The most recent analyst rating on (CV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.

CapsoVision Appoints David Garcia as Finance VP

On November 3, 2025, CapsoVision, Inc. announced the appointment of David Garcia as its Senior Vice President of Finance, who will also serve as the principal financial officer and principal accounting officer. Mr. Garcia brings over 20 years of financial leadership experience, having previously worked at Matterport, Inc., View, Inc., Intelepeer Cloud Communications, and Align Technology. His appointment is seen as a strategic move to support CapsoVision’s growth and development pipeline, leveraging his expertise in financial management and capital markets.

The most recent analyst rating on (CV) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.